Moderna, Inc. (MRNA)
Overview · Option chain · Volatility · Expected-move history · Earnings
Cboe delayed options data · as of Sep 02, 21:52 UTC · Figures derived from the full chain (2,102 contracts, 16 expirations) · IV own-history percentile appears after 60 recorded days (3 so far)
Expected move — Sep 18, 2026 (16 days)
Methodology →Read from option prices: the at-the-money straddle costs this much, so the market is pricing a move of about that size in either direction by this date. It is an estimate of movement, not a prediction of direction.
Options are pricing a move of about ±13.1% (range 130.62–169.97) by Sep 18, 2026. ATM straddle: 19.68 @ strike 150 · ATM IV: 78.2%.
Probability distribution
Model & assumptions →The curve shows where a lognormal model, fed with current implied volatility, puts the range of outcomes at this expiration. Shaded: the expected-move band.
| Level | vs price | P(above)Model-estimated chance the stock finishes above a level at expiration, derived from current IV under a lognormal model with stated assumptions — an estimate, not a prediction. | P(below) |
|---|---|---|---|
| 135.27 | -10% | 71.3% | 28.7% |
| 142.78 | -5% | 59.2% | 40.8% |
| 150.30 | +0% | 46.7% | 53.3% |
| 157.82 | +5% | 35.2% | 64.8% |
| 165.33 | +10% | 25.3% | 74.7% |
Model-estimated probabilities of finishing above/below each level at expiration — estimates under stated assumptions, not predictions.
Probability explorer
Drag the slider to any level and see the model-estimated chance the stock finishes above or below it at the selected expiration.
Horizon: Sep 18, 2026 · lognormal model, zero drift — an estimate, not a prediction. Assumptions
Expirations
Open the chain →| Expires | DTEDays to expiration, in calendar days. | Implied move | ATM IV | Open int. |
|---|---|---|---|---|
| Sep 04, 2026 | 2 | ±5.4% | 90.9% | 115.6K |
| Sep 11, 2026 | 9 | ±9.6% | 76.3% | 34.4K |
| Sep 18, 2026 | 16 | ±13.1% | 78.2% | 180.1K |
| Sep 25, 2026 | 23 | ±15.5% | 77.3% | 17.4K |
| Oct 02, 2026 | 30 | ±17.6% | 77.0% | 13.9K |
| Oct 09, 2026 | 37 | ±19.6% | 77.2% | 1,417 |
| Oct 16, 2026 | 44 | ±21.8% | 78.9% | 68.7K |
| Nov 20, 2026 | 79 | ±31.0% | 84.1% | 63.0K |
| Dec 18, 2026 | 107 | ±35.1% | 82.0% | 118.6K |
| Jan 15, 2027 | 135 | ±39.2% | 81.8% | 191.3K |
| Mar 19, 2027 | 198 | ±46.1% | 80.0% | 37.2K |
Open interest by strike — Sep 18
Where option positions are concentrated. Teal bars are calls, red bars are puts; the dashed line is the current price.
Largest open-interest concentrations (all expirations ≤ 60 days): 120 P · 28.3K180 C · 13.8K100 P · 13.5K125 P · 13.2K80 P · 12.7K
IV term structure
Volatility page →At-the-money implied volatility for each expiration. A hump around a date often marks a scheduled event the market is pricing.
When does open interest expire?
Implied vs realized volatility
HV from our stored daily closes (annualized); IV30 interpolated from the chain. Method
Price, last 60 sessions
Track record
Full history →Every trading day we record what the options market is pricing for each expiration — before the outcome is known. Once expirations start resolving, this section compares expected versus actual, and the record is never rewritten. Recording since Aug 31, 2026.
Past earnings reactions
Avg |reaction| 9.8% · median 8.1% (20 reports) — two-session close-to-close window; definition
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strate
Healthcare · Biotechnology · NASDAQ · Profile: Financial Modeling Prep
MRNA news
All news →S&P 500 biggest August 2026 winners: Moderna, software stocks
Yahoo Finance · Sep 02, 21:03 UTC ↗Related securities — Healthcare
PFE · IV 21.8%HIMS · IV 67.0%UNH · IV 27.3%LLY · IV 31.7%JNJ · IV 23.2%MDT · IV 23.5%